Noninvasive markers of fibrosis for longitudinal assessment of fibrosis in chronic liver disease: Are they ready for prime time?

American Journal of Gastroenterology

Volumn 101, Issue 7, 2006, Pages 1497-1499

  Thuluvath, Paul J ^a,b   Krok, Karen L ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA 2 MACROGLOBULIN; AMINO TERMINAL TELOPEPTIDE; APOLIPOPROTEIN A1; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; BIOLOGICAL MARKER; COLLAGEN TYPE 3; COLLAGEN TYPE 4; GAMMA GLUTAMYLTRANSFERASE; HAPTOGLOBIN; HYALURONIC ACID; INTERSTITIAL COLLAGENASE; LAMININ; LAMIVUDINE; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TRANSFORMING GROWTH FACTOR BETA1;

CHRONIC LIVER DISEASE; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; DIAGNOSTIC VALUE; DISEASE MARKER; HEPATITIS B; HISTOPATHOLOGY; HUMAN; LABORATORY DIAGNOSIS; LIVER FIBROSIS; NON INVASIVE MEASUREMENT; PREDICTION; PREDICTIVE VALIDITY; PRIORITY JOURNAL; PROTEIN DEGRADATION; RELIABILITY; REVIEW; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY;

BIOLOGICAL MARKERS; CHRONIC DISEASE; FIBROSIS; HUMANS; LIVER CIRRHOSIS; LIVER DISEASES; LONGITUDINAL STUDIES;

EID: 33745565323     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2005.00304.x     Document Type: Review

References (19)

1. James CH, Lindor KD. Outcome of patients admitted with complications after outpatient liver biopsies. Ann Intern Med 1993;118:96-8.
2. McGill DB, Rakela J, Zinsmeister AR, et al. A 21-year experience with major hemorrhage after percutaneous liver biopsy. Gastroenterology 1990;99:1396-400.
3. Westin J, Lagging LM, Wejstal R, et al. Interobserver study of liver histopathology using the Ishak score in patient with chronic hepatitis C virus infection. Liver 1999;19:183-7.
4. Bedossa P, Dargere D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003;38:1449-57.
5. Regev A, Berhho M, Jeffers LJ, et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 2002;97:2614-18.
6. Imbert-Bismut F, Ratziu V, Pieroni L, et al. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection. Lancet 2001;357:1069-75.
7. Forns X, Ampurdanes S, Llovet JM, et al. Identification of chronic hepatitis C patients without hepatic fibrosis by simple predictive model. Hepatology 2002;36:986-92.
8. Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003;38:518-26.
9. Rosenberg WM, Voelker M, Thiel R, et al. Serum markers detect the presence of liver fibrosis: A cohort study. Gastroenterology 2004;127:1704-13.
10. Saitou Y, Shiraki K, Yamanaka Y, et al. Noninvasive estimation of liver fibrosis and response to interferon therapy by a serum fibrinogenesis marker, YKL-40, in patients with HCV-associated liver disease. World J Gastroenterol 2005;11:476-81.
11. Callewaert N, Van Vlierberghe H, Van Hecke A, et al. Noninvasive diagnosis of liver cirrhosis using DNA sequencer-based total serum protein glycomics. Nat Med 2004;10:429-34.
12. Caster L, Vergniol J, Foucher J, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005;1128:343-50.
13. Park GJ-H, Katelaris PH, Jones DB, et al. Validity of C-caffeine breath test as a non-invasive, quantitative test of liver function. Hepatology 2003;38:1227-36.
14. Poynard T, Zoulim F, Ratziu V, et al. Longitudinal assessment of histology surrogate markers (Fibrotest-Actitest) during lamivudine therapy in patients with chronic hepatitis B infection. Am J Gastroenterol 2005.
15. Halfon P, Imbert-Bismut F, Messous D, et al. A prospective assessment of inter-laboratory variability markers of fibrosis (FibroTest) and activity (ActiTest) in patients with chronic liver disease. Comp Histol 2002;1:3.
16. Rossi E, Adams L, Prins A, et al. Validation of Fibro test biochemical markers score in assessing liver fibrosis in hepatitis C patients. Clin Chem 2003;49:450-54.
17. Myers RP, Tainturier MH, Ratziu V, et al. Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B. J Hepatol 2003;39:222-30.
18. Rosenthall-Allieri MA, Peritore ML, Tran A, et al. Analytical variability of the Fibrotest proteins. Clin Biochem 2005;38:473-8.
19. Bissell DM. Assessing fibrosis without a liver biopsy: Are we there yet? Gastroenterology 2004;127:1847-9.